Novartis pays $7.8 billion for Abogen mRNA asset
Novartis agreed to pay up to $7.8 billion for global rights to an early-stage mRNA therapy from China's Abogen Biosciences, the latest and largest in
Summit Therapeutics
Every Fin-node story mentioning Summit Therapeutics — 2 stories, newest first.
Summit Therapeutics · 2 stories
AstraZeneca puts $2 billion into Summit Therapeutics
AstraZeneca agreed to invest $2 billion in Summit Therapeutics on Monday, sending the biotech’s shares up as much as 19 percent in after-hours trading